# Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Study · id `cardio:ct-nct02057172` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02057172](<https://clinicaltrials.gov/study/NCT02057172>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02057172

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.

## Technical summary

Registry record NCT02057172. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 254 participants (enrolled count; ClinicalTrials.gov record NCT02057172, source copy `cardio:ctgov-nct02057172-2016-08-09`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT02057172, source copy `cardio:ctgov-nct02057172-2016-08-09`, retrieved 2026-10-26)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT02057172, source copy `cardio:ctgov-nct02057172-2016-08-09`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT02057172, source copy `cardio:ctgov-nct02057172-2016-08-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02057172, source copy `cardio:ctgov-nct02057172-2016-08-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02057172-2016-08-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): HM11260C
- Intervention (Drug): liraglutide
- Intervention (Drug): Placebo
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide (`cardio:pubmed-31320446`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3e3d8bf33cca0e87af4534d5c890be0053dad7f0e59bfb8727d6a55ef8aa3974
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
